Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Interest & Investment Income (2020 - 2026)

Immuneering's Interest & Investment Income history spans 7 years, with the latest figure at $1.4 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 210.23% to $1.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.0 million, a 77.88% increase, with the full-year FY2025 number at $3.0 million, up 17.2% from a year prior.
  • Interest & Investment Income came in at $1.4 million for Q1 2026, down from $1.9 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $1.9 million in Q4 2025, with the low at $132506.0 in Q1 2022.
  • Historically, Interest & Investment Income has averaged $683209.8 across 5 years, with a median of $547072.0 in 2024.
  • Biggest five-year swings in Interest & Investment Income: soared 4281.68% in 2022 and later crashed 60.78% in 2025.
  • Year by year, Interest & Investment Income stood at $516168.0 in 2022, then surged by 46.1% to $754144.0 in 2023, then crashed by 44.94% to $415240.0 in 2024, then soared by 348.19% to $1.9 million in 2025, then decreased by 26.9% to $1.4 million in 2026.
  • Business Quant data shows Interest & Investment Income for IMRX at $1.4 million in Q1 2026, $1.9 million in Q4 2025, and $415831.0 in Q3 2025.